A
Accuracy of pap-smear 182
Acid-fast bacilli (AFB) 167
Activated protein C resistance 62
Activin/inhibin system 94
Adenocarcinoma in situ (AIS) 215
Adenomyosis 57
Adequate smear 181
Adolescent age group 41
Adrenal contribution 94
Age and parity 111
Agonist in uterine leiomyoma (LM) 123
Alternative treatment 77
Alzheimer's disease 68
Amenorrhea/oligomenorrhea 56
Androgen insensitivity syndrome (XY) 10
Anterior compartment defect 152
Anticardiolipin antibody syndrome 62
Antioxidant activity 64
Applied anatomy 152
Archibald Mcindoe's operation 11
C
Ca cervix 228
Carbon dioxide (CO2) 133
Carcinogenic effect 56
Catecholamines and other neuronal factors 94
Categories of hormonal contraceptives 32
Central defects 153
Cervix or vault 151
Changes in intraovarian milieu 93
Chlamydia trachomatis 192
Classification of primary amenorrhea 6
Clear cell carcinoma 217
Clomiphene citrate (CC) 106
COC and
cancer risk 38
carcinoma of breast 39
carcinoma of ovary 39
other cancers 39
subsequent fertility 36
Cold light source 77
Colposcopic punch biopsy 211
Combination of estrogen and progestogen 46
Combined preparations 60
Common hypercoagulable states 62
Complete blood count 63
Conclusions from literature 79
Conisation of cervix 212
Controlled ovarian hyperstimulation (COH) 106
Copper impregnated devices 51
Cornual resection 77
Coronary artery disease 62
Criteria for patient selection 76
Cryopreservation of ovarian tissue for purpose 241
Curettage if problem continues 42
Cyclofem 32
Cytogenetics of complete moles 83
D
Decreases level of antithrombin 63
Deficiency of protein C 62
Degree of protection 182
Delaying administration of hCG 108
Dendritic cells and Langerhans' cells 190
Denonvillier's fascia 153
Depot medroxy progesterone acetate (DMPA) 41
Dilatation and curettage (D and C) 26
Disadvantages of GnRHa therapy 126
DMPA and neoplasia 44
Drugs used throughout cycle 28
Dysmenorrhea 57
E
Effect of
chemotherapy in males 234
DMPA on fetus 45
dopamine agonist therapy on fetus 147
estrogen in pill 33
estrogen on coagulation 63
hyperandrogenism 96
pregnancy on prolactinomas 146
radiation and chemotherapy 233
Effects on protein metabolism 36
Embryo transfer (ET) 177
Emergency surgery in pregnancy 149
Endocervical curettage 211
Endoscopic procedures 101
Enterocele 151
Enucleation of myoma 115
Epidemiology and transmission of genital HPV 187
Epilepsy 68
Estimated TB incidence and mortality 165
Estrogen
and progestins 32
nondependant 217
Ethinylestradiol 32
Ethisterone derivative 140
Examination of biopsy specimens 210
Excisional and destructive methods of treatment 211
Expectant treatment 76
Expulsion rate 56
Extraglandular estrogens 96
F
Factors predicting onset of menarche 3
Familial hypertriglyceridemia 64
Fasting serum insulin levels 99
Fertility sparing management of gynecological malignant 208
Fibroids 57
First generation of combined oral contraceptive 33
Follicle stimulating hormone (FSH) 1
Frank technique or perineal dilation 13
Freezing of ovarian cortical strips 242
Full blood count (FBC) 25
Functional ovarian cysts 56
Future II trial 195
G
Gallbladder disease 41
Gallstones 64
Gamma-amino butyric acid (GABA) 145
Genesis of partial mole 83
Germ cell tumors of ovary 226
Global advisory committee on vaccine safety (GACVS) 196
GnRH 28
Gonadotropins (GTH) 1
Grisofulvin 34
Gross hematuria 161
Gunasheela IVF center 175
H
Hemocoagulase injection 129
Hemostatic evaluation 63
Heterosexual development of SSC 18
High false negativity 181
High flow CO2 insufflator 77
High grade lesions (HGSIL) 185
Hirsutism and acne 100
Histogenetic classification of ovarian neoplasms 222
Histomorphological features of polycystic ovaries 92
Holding hCG 108
Hot flushes, night sweats 62
HRT in women “at risk” for breast cancer 67
Hydatidiform mole with a coexistent live fetus 82
Hydroxyethyl starch (HES) 108
Hyperandrogenemia in PCOS 94
Hyperandrogenism (HA) 91
Hyperandrogenism in PCOS 102
Hypergonadotropic situation 14
Hyperinsulinemic insulin resistance 103
Hypermobility SUI 159
Hypoestrogenaemia in PCOS 95
Hypomenorrhea 23
Hysterosalpingogram (HSG) 171
Hysteroscopy 26
I
Immunogenicity of prophylactic vaccines 193
Impact of chemotherapeutic agents on ovarian function 234
Impaired insulin secretion 63
Imperforate hymen 8
Improve smear quality 182
Inappropriate gonadotropin secretion 92
Indications for ovarian drilling 102
Inert devices 51
Injectable contraceptives 41
Insertion technique 57
Interaction with drugs 34
Intramural fibroids 129
Intrapartum care 149
Intrauterine
contraceptive devices (IUCDS) 51
Intravenous albumin 108
Intrinsic sphincter deficiency (ISD) 158
Invasive ovarian carcinoma 225
Investigation of delayed puberty 4
Isolated GnRH deficiency 14
L
Lactating women 56
Laparoscopic
colposuspension 160
cystocele repair 154
enterocele repair 155
sacrospinous ligament suspension 156
vaginal vault suspension 156
Lateral defects 153
Leiomyoma uteri 68
Levels of FSH and LH hormones 1
Linear salpingostomy 77
Lipid profile 99
Liver and COC users 37
Lletz specimen and cone biopsy 211
LN biodegradable 32
Long-term health risks 103
Looking to the future 70
Loop excision of transformation zone (LLETZ) 212
Löwenstein-Jensen (LJ) 167
M
Magnetic resonance imaging (MRI) 129
Major complications of conisation 212
Malignancy 65
Management of
androgen insensitivity syndrome 17
CIN and microinvasive disease 213
hypogonadotropic amenorrhea 15
low grade lesions 185
myomas 113
PCOS in young unmarried girls 99
Mayer-Rokitansky syndrome (MRS) 10
Medroxy progesterone actate 32
Metabolic effects of DMPA 44
Method of evacuation 88
Methodology of smear taking 180
Microadenomas 149
Middle compartment defect 152
Migraine 68
Minor effects with COC 38
Miscarriage rate 101
Macroadenomas 149
Mode of action of GnRH agonist 235
Molar pregnancy with coexistent normal fetus 85
Monitoring during pregnancy 148
Morcellation of myoma 118
Multiple pregnancy 101
Myocardial infarction 65
Myomas and laparoscopic myomectomy 110
Myomectomy 114
N
National family welfare program 32
Native GnRH 122
Natural history of HPV infection 189
Needle bladder neck suspension 159
Neoplasms metastatic to ovary 222
Nonhormonal methods 47
Nonspecific hemostatic agents 42
Norethisterone enanthate 32
Norethyndrone enanthate (NET EN) 41
Noristerat 41
Norplant and norplant II systems 32
O
Obstetric history 220
Oligomenorrhagia 23
Oligomenorrhea 23
One month after delivery 150
Open reading frame (ORF) 187
Operative technique 114
Oral contraceptive (OC) for fertility preservation 235
Oral contraceptives 32
Osteoporosis 62
Outcome after ovarian diathermy 101
P
Papillary (high grade) serous carcinoma 217
Paravaginal suspension 154
Pathogenesis of PCOS 92
Patient with macroprolactinomas 147
Patricia trial 194
PCOS an inherited disorder 98
Perimenopausal age group 41
Persistent ectopic pregnancy 79
Pharmacology of combined oral contraceptives 32
Phytoestrogens 70
Pif–prolactin inhibiting factor 145
Pitfalls in ultrasound scan 75
Placement of adhesion barrier 119
Plasminogen activation inhibitor 98
Polycystic ovarian syndrome 91
Polymenorrhagia 23
Polymenorrhea 23
Population reports 45
Port placement 115
Postcoital contraception 46
Posterior compartment defect 152
Postmenopausal women 185
Postponement of embryo transfer (ET) 108
Pouch of Douglas 138
Precancerous conditions 23
Preparation of vaginal mould 11
Pressure effects on other organs 125
Progestogens 28
Prognostic factors 218
Progressive potential of CIN 210
Prophylactic vaccine 197
Protegen sling 162
Protocol for multidose therapy 76
R
Raised HDL level 64
Receptors in endometrium 217
Re-construction of vagina 11
Rectocele and perineum 151
Regarding HRT 62
Relevance of hormonal assay in evaluation 99
Resistant ovarian syndrome (XX) 15
Responsibility of treating oncologist 228
Retropubic urethropexy 159
S
Sacral colpopexy 156
Sacrospinous vaginal vault suspension 156
Safety concerns with ovarian transplantation 244
Safety of the prophylactic vaccines 196
Salpingectomy 77
Second generation of combined oral contraceptive 33
Secondary sexual characteristics (SSC) 3
Segmental resection 77
Separation of crux levators 155
Serum DHEAs/DHEA 99
Seven-step approach for decisions 62
Sex cord stromal tumors 226
Sexually transmitted diseases 180
Side effects of danazol therapy 140
Smear interpretation 181
Squamous intraepithelial lesions (SIL) 209
SSC present—true amenorrhea 9
Stein Leventhal syndrome 91
Stimulating hormone (FSH) 122
Strategies for prevention of OHSS 107
Submucosal fibroids 128
Subserosal fibroids 129
Suppresses FSH 34
Surgery for stress urinary incontinence (SUI) 152
T
Tamoxifen for induction of ovulation 236
Target group for vaccination 197
Tension-free vaginal tape (TVT) 162
Teratogenic effect 56
Testicular feminizing syndrome 15
Testosterone in use 60
Th1 immune response 191
Th2 immune response 191
Third generation of combined oral contraceptive 33
Thrombosis and/or phlebitis 62
Thyroid function tests (TFTS) 25
Thyrotropin releasing hormone (TRH) 145
Time of insertion of IUCD 55
Trichomonas vaginalis 192
Trouble shooting during hysteroscopy 136
Tuberculosis (TB) 165
U
Ultrasonography 26
Ultrasound scan 75
Undetermined vaginal bleeding 70
Unwanted side effects 42
Urethra 151
Urodynamic study 159
Use of 1.5% glycine 135
aromatase inhibitor (letrozole) for inducti 237
carbon dioxide 133
crystalloid and dextrose solution 134
GnRH analog
along with chemoadjuvant therapy 235
in treatment of myoma 122
GnRH therapy in endometriosis 141
IVF and embryo transfer 165
ovarian grafts in non-cancerous conditions 243
uterine arterial embolization in treatment 128
Viscous media 135